Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer

Overview of attention for article published in Bladder Cancer, April 2016

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 11 X users

Readers on

mendeley: 71 Mendeley

So far, Altmetric has seen 11 X posts from 11 X users, with an upper bound of 77,617 followers.

RT @ERPlimackMD: @pcvblack @wandering_gu @TheWonkologist "for patients in the BCG unresponsive category... a clinically meaningful initial…

@pcvblack @wandering_gu @TheWonkologist "for patients in the BCG unresponsive category... a clinically meaningful initial CR rate (for CIS) or recurrence-free rate (for papillary tumors) of at least 50% at 6 months, 30% at 12 months and 25% at 18 months…

RT @montypal: Nice summary @OncoBellmunt @apolo_andrea @UroDocAsh of a very productive mtg @NCI for #NMIBC @B_C_A_N https://t.co/rNyJ2loMiR

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 7 additional X posts.